Thyroid tumorigenesis and molecular markers in thyroid cancer

Kouniavsky, Guennadi; Zeiger, Martha A.

doi:10.1097/cco.0b013e328333846f

Cited by 39 publications

(22 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the factors considered to be responsible for the increase of PTC appears to be an increase in the supply of iodine in the general population (13). Additionally, genetic factors have also been proposed as a contributory factor (14-16), between 5 and 10% of PTCs are known to be familial (17). Furthermore, increased awareness for thyroid cancer risks after the Chernobyl nuclear accident may be an additional factor.…”

Section: Introductionmentioning

confidence: 99%

Rising Incidence of Small Size Papillary Thyroid Cancers with No Change in Disease-Specific Survival in Finnish Thyroid Cancer Patients

et al. 2012

View full text Add to dashboard Cite

Background: the aim of this study was to investigate trends in the incidence, diagnostics, treatment and survival of thyroid cancer in tampere university hospital (tauh) region in recent decades.Material and Methods: new thyroid cancer cases from 1981 to 2002 were ascertained from the finnish cancer Registry. follow-up data was collected from medical records of tauh. differentiated thyroid cancer (dtc; consisting of papillary thyroid cancer (ptc) and follicular thyroid cancer (ftc)) patients' data was analyzed and divided into two equal time periods (1981-1991 and 1992-2002).Results: the total amount of thyroid cancer cases was 553, of which 427 (77%) were papillary and 72 (13%) follicular. thyroid cancer was four times more common in females than in males and the median age at the time of diagnosis was 52 years. the incidence of dtc was 4.5/100 000 in the earlier group and 6.0/100 000 in the later group (iRR 1.33, ci 1.11-1.60). the proportion of papillary thyroid cancer rose from 81% to 89% (p = 0.02) in two study periods. median tumour size became smaller, from 25 mm to 15 mm (p < 0.001). surgery became more radical as total thyroidectomies were performed almost exclusively on the later group (p < 0.001). median cumulative dose of radioiodine (i 131 ) therapy was higher in the later group (p = 0.04). there was no difference in number of cancer recurrences (p = 0.54). the prognosis of dtc was good; 10-year diseasespecific survival was 92% in the earlier group and 94% in the later group (p = 0.43).Conclusions: the incidence of thyroid cancer has risen and proportion of papillary cancer has increased, however, median size of tumour has decreased. no difference was seen in either all-cause or disease-specific survival.

show abstract

Section: Introductionmentioning

confidence: 99%

Rising Incidence of Small Size Papillary Thyroid Cancers with No Change in Disease-Specific Survival in Finnish Thyroid Cancer Patients

et al. 2012

View full text Add to dashboard Cite

show abstract

“…A combination of other diagnostic procedures have been used to solve the problem, such as the safe, sensitive, and straightforward ultrasonography method; however, this method is only effective with suspicious thyroid nodules, and is ineffective with improving the accuracy of FNAB cytology in indeterminate lesions (Banks et al, 2008;Dean and Gharib, 2008). Furthermore, no efficient immunohistochemical and molecular markers can reliably determine which of these patients can avoid unnecessary thyroidectomy, although great efforts have been made in recent years toward this end (Shibru et al, 2008;Stang and Carty, 2009;Vriens et al, 2009;Chudova et al, 2010;Kouniavsky and Zeiger, 2010;Adeniran et al, 2011). Thus, safe and accurate novel biomarkers are still urgently needed as a second-line diagnostic tool to determine malignancy with a high accuracy level for patients with indeterminate lesions.…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs as novel biomarkers for the differentiation of malignant versus benign thyroid lesions: a meta-analysis

Zhou¹,

Xiao²,

Zhao³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The aim of this meta-analysis was to systematically evaluate the diagnostic accuracy of microRNAs (miRNAs) in distinguishing malignant thyroid lesions from benign ones and to determine the potential of miRNAs as diagnostic biomarkers for thyroid cancer. The random-effect model was used to summarize the pooled estimates of diagnostic accuracy, including sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The summary receiver-operating characteristic curve (SROC) and area under the SROC curve (AUC) were used to further evaluate the overall diagnostic value. Overall, 20 studies from 7 articles, including 266 thyroid cancer patients and 277 controls with benign thyroid disease, were available for analysis. The pooled sensitivity, specificity, PLR, NLR, and DOR were: 0. 7279-7289 (2015) 0.95 versus 0.82, suggesting that the multiple miRNA assay is a more credible method for thyroid cancer detection. In summary, miRNA assays, especially multiple miRNA assays, may play an important role as a second-line diagnostic tool to improve the diagnostic accuracy of fine needle aspiration biopsy in indeterminate lesions. However, further studies are warranted to confirm our findings.

show abstract

“…Another gene, DCSTAMP (TM7SF4), located in 8q23 was demonstrated to be associated with PTC by others [9]. Both thyroglobulin and Src-like adaptor (SLA) genes are located in this region [36]. This underlies the importance of the 8q24 locus in terms of PTC [36].…”

Section: Discussionmentioning

confidence: 94%

Differential Expression of a Set of Genes in Follicular and Classic Variants of Papillary Thyroid Carcinoma

et al. 2011

View full text Add to dashboard Cite

Fine-needle aspiration biopsy (FNA) is currently the best initial diagnostic test for evaluation of a thyroid nodule. FNA cytology cannot discriminate between benign and malignant thyroid nodules in up to 30% of thyroid nodules. Therefore, an adjunct to FNA is needed to clarify these lesions as benign or malignant. Using differential display-polymerase chain reaction method, the gene expression differences between follicular and classic variants of papillary thyroid carcinoma (PTC) and benign thyroid nodules were evaluated in a group of 42 patients. Computational gene function analyses via Cytoscape, FuncBASE, and GeneMANIA led us to a functional network of 17 genes in which a core sub-network of five genes coexists. Although the exact mechanisms underlying in thyroid cancer biogenesis are not currently known, our data suggest that the pattern of transformation from healthy cells to cancer cells of PTC is different in follicular variant than in classic variant.

show abstract

Thyroid tumorigenesis and molecular markers in thyroid cancer

Abstract: With ongoing research, clinical problems such as the suspicious thyroid fine needle aspiration, better treatment algorithms for well differentiated thyroid cancer, and more effective treatment for anaplastic cancer will likely be found.

Cited by 39 publications

References 47 publications

Rising Incidence of Small Size Papillary Thyroid Cancers with No Change in Disease-Specific Survival in Finnish Thyroid Cancer Patients

Rising Incidence of Small Size Papillary Thyroid Cancers with No Change in Disease-Specific Survival in Finnish Thyroid Cancer Patients

MicroRNAs as novel biomarkers for the differentiation of malignant versus benign thyroid lesions: a meta-analysis

Differential Expression of a Set of Genes in Follicular and Classic Variants of Papillary Thyroid Carcinoma

Contact Info

Product

Resources

About